Q3 2025 Avanos Medical Inc Earnings Call Transcript

Nov 5, 2025 / 02:00 PM GMT

Release Date Price: €9.7 (+2.11%)

Transcript 10-Q8-K

Key Points

Positve

Avanos Medical Inc (AVNS) reported strong growth in its specialty nutrition systems segment, with organic sales up 10% compared to the previous year.
The company achieved double-digit growth in its radio frequency ablation business, contributing to positive year-over-year growth in the pain management and recovery segment.
Avanos Medical Inc (AVNS) raised its full-year revenue estimates to $690 to $700 million and adjusted EPS estimate to $0.85 to $0.95 per share, reflecting strong sales momentum and effective cost discipline.
The acquisition of Nexus Medical is expected to be immediately accretive to both revenue and earnings per share, expanding the company's presence in the neonatal and pediatric markets.
The company has identified cost-saving opportunities expected to deliver $15 to $20 million in annualized incremental cost savings by the end of 2026.

Negative

The current tariff environment continues to impact Avanos Medical Inc (AVNS), with an estimated $18 million impact on the P&L due to incremental tariff-related manufacturing costs.
The company anticipates lower year-over-year growth in the fourth quarter for its Neomed product line due to one-off tailwinds in the prior year.
Avanos Medical Inc (AVNS) experienced a decline of over 20% in its hyaluronic acid injections and intravenous infusion product lines due to the divestiture of the HA business.
The surgical pain business was flat in the third quarter compared to the prior year, with delays in the implementation of the reimbursement decision O Pay Act.
Higher capital expenditures are anticipated in 2025 to support strategic supply chain initiatives and accelerate the company's exit from China, impacting free cash flow.

Refinitiv StreetEvents Event Transcript
P R E L I M I N A R Y V E R S I O N

AVNS.N - Avanos Medical Inc
Q3 2025 Avanos Medical Inc Earnings Call
Nov 05, 2025 / 02:00PM GMT

=====================
Conference Call Participants
=====================
* >>NOTE
* >>Transcription Start

=====================
Presentation
--------------------------------------------------------------------------------
>>NOTE [1]
--------------------------------------------------------------------------------

THIS TRANSCRIPT IS THE INITIAL PRELIMINARY VERSION WHICH LEVERAGES MACHINE LEARNING TECHNOLOGY. AS SUCH, PLEASE BE AWARE THERE MAY BE INACCURACIES IN THE TEXT DISPLAYED. FUTURE EDITED VERSIONS WILL BE REVIEWED FOR GREATER ACCURACY.

--------------------------------------------------------------------------------
>>Transcription Start, [2]
--------------------------------------------------------------------------------

Third quarter results and the current business environment, no details regarding these topics and update our 2025 plan. We will

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.